US Pharma MarketingUCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week 16. The difference was statistically significant, UCB said. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week 16. The difference was statistically significant, UCB said.
Source: FiercePharma